{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:45:38Z","timestamp":1786740338484,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007586","name":"Aix-Marseille Universit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020986","name":"Innate Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["Treatlivmets, grant agreement 101118936"],"award-info":[{"award-number":["Treatlivmets, grant agreement 101118936"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PLBIO23-061"],"award-info":[{"award-number":["PLBIO23-061"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006331","name":"Cancerop\u00f4le PACA","doi-asserted-by":"publisher","award":["Emergence Grant 2022"],"award-info":[{"award-number":["Emergence Grant 2022"]}],"id":[{"id":"10.13039\/501100006331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.it.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:34:42Z","timestamp":1786682082000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["NK cells in breast cancer"],"prefix":"10.1016","author":[{"given":"Andr\u00e9a","family":"Massidda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moragon-Terencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille Baudesson","family":"de Chanville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Narni-Mancinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2026.07.007_bb0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.it.2026.07.007_bb0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.07.007_bb0015","doi-asserted-by":"crossref","first-page":"10935","DOI":"10.1007\/s11033-022-07865-5","article-title":"The role of the natural killer (NK) cell modulation in breast cancer incidence and progress","volume":"49","author":"Razeghian","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.it.2026.07.007_bb0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1210\/endrev\/bnaf014","article-title":"The roles of natural killer cells in breast cancer pathobiology and their regulation by estrogens","volume":"46","author":"Byemerwa","year":"2025","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.it.2026.07.007_bb0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-024-00712-9","article-title":"Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative","volume":"10","author":"Shin","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb0030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41523-025-00881-1","article-title":"Immune-stromal heterogeneity in breast cancer across diverse ancestries: impact on prognosis and treatment response","volume":"11","author":"Alamukii","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13058-025-02038-1","article-title":"Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping","volume":"27","author":"Cheung","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb0040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.07.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432442","article-title":"Systemic therapy in breast cancer","volume":"44","author":"Corti","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.it.2026.07.007_bb0050","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2026.07.007_bb0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clbc.2024.03.001","article-title":"The role of immunotherapy in triple-negative breast cancer (TNBC)","volume":"24","author":"Michaels","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb0060","article-title":"Neoadjuvant immunotherapy in hormone receptor-positive breast cancer: from tumor microenvironment reprogramming to combination therapy strategies","volume":"26","author":"Tang","year":"2025","journal-title":"IJMS"},{"key":"10.1016\/j.it.2026.07.007_bb0065","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/s41467-025-58511-0","article-title":"Spatially resolved atlas of breast cancer uncovers intercellular machinery of venular niche governing lymphocyte extravasation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.07.007_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13058-025-01964-4","article-title":"Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers","volume":"27","author":"Ehlers","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb0075","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(24)00747-5","article-title":"The Lancet Breast Cancer Commission","volume":"403","author":"Coles","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.it.2026.07.007_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Beano","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.it.2026.07.007_bb0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.07.007_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.898745","article-title":"Role of the ITAM-bearing receptors expressed by natural killer cells in cancer","volume":"13","author":"Medjouel Khlifi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb0095","first-page":"122","article-title":"Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates","volume":"2","author":"Wong","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.it.2026.07.007_bb0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.07.007_bb0110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","article-title":"High-dimensional single-cell analysis of human natural killer cell heterogeneity","volume":"25","author":"Rebuffet","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb0115","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb0120","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.4049\/jimmunol.1200140","article-title":"Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets","volume":"190","author":"Mamessier","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb0125","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2026.07.007_bb0130","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tranon.2016.07.003","article-title":"Altered expression of natural cytotoxicity receptors and NKG2D on peripheral blood NK cell subsets in breast cancer patients","volume":"9","author":"Nieto-Vel\u00e1zquez","year":"2016","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.it.2026.07.007_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818764499","article-title":"Expression of NK cell surface receptors in breast cancer tissue as predictors of resistance to antineoplastic treatment","volume":"17","author":"Garcia-Chagollan","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.it.2026.07.007_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1255","article-title":"Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer","volume":"12","author":"Darvishvand","year":"2024","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.it.2026.07.007_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-024-00638-2","article-title":"Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation","volume":"10","author":"Chauhan","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-015-0535-8","volume":"13","author":"Verma","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2555","article-title":"Natural Killer Cell Phenotype and Function as a Predictive Factor for Treatment Response to Neoadjuvant Therapy in Breast Cancer Patients","volume":"27","author":"Anguiano Serrato","year":"2026","journal-title":"IJMS"},{"key":"10.1016\/j.it.2026.07.007_bb2015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","article-title":"Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping","volume":"25","author":"Netskar","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2020","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2018.02028","article-title":"Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer","volume":"9","author":"Foulds","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cellimm.2015.09.002","article-title":"Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-\u03b2 in healthy donors and breast cancer patients","volume":"298","author":"Ostapchuk","year":"2015","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00262-014-1629-5","article-title":"CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo","volume":"64","author":"Wennerberg","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.07.007_bb2035","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12094-022-02997-3","article-title":"Suppression of CD56bright NK cells in breast cancer patients is associated with the PD-1 and TGF-\u03b2RII expression","volume":"25","author":"Arianfar","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.it.2026.07.007_bb2040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002044","article-title":"TGF\u03b2 drives NK cell metabolic dysfunction in human metastatic breast cancer","volume":"9","author":"Slattery","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb2045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13058-024-01932-4","article-title":"Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer","volume":"26","author":"Han","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb2050","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818764499","article-title":"Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment","volume":"17","author":"Garcia-Chagollan","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.it.2026.07.007_bb2055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1479-5876-11-145","article-title":"Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients","volume":"11","author":"Ascierto","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41540-025-00549-3","article-title":"Single-cell transcriptomic profiling of immune landscape in triple-negative breast cancer during neoadjuvant chemotherapy","volume":"11","author":"Patysheva","year":"2025","journal-title":"npj Syst. Biol. Appl."},{"key":"10.1016\/j.it.2026.07.007_bb2065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00251-025-01383-x","article-title":"Dysregulation of lncRNAs in NK cells from breast cancer patients: implications for NK cell functions","volume":"77","author":"Rady","year":"2025","journal-title":"Immunogenetics"},{"key":"10.1016\/j.it.2026.07.007_bb2070","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verg\u00e8s","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.07.007_bb2075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.coi.2007.04.004","article-title":"Natural killer cells: from CD3\u2212NKp46+ to post-genomics meta-analyses","volume":"19","author":"Walzer","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2080","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","article-title":"Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging","volume":"174","author":"Goltsev","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.07.007_bb2085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.it.2026.07.007_bb2090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.it.2026.07.007_bb2095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13058-025-01964-4","article-title":"Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers","volume":"27","author":"Ehlers","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb2100","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1158\/1078-0432.CCR-18-2365","article-title":"NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival","volume":"25","author":"Muntasell","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb2105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/2159-8290.CD-24-0131","article-title":"Cancer-Associated Fibroblasts Serve as Decoys to Suppress NK Cell Anticancer Cytotoxicity in Breast Cancer","volume":"15","author":"Ben-Shmuel","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.07.007_bb2110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13058-025-02003-y","article-title":"Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy","volume":"27","author":"Wang","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.it.2026.07.007_bb2115","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.7150\/ijbs.108803","article-title":"Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategies","volume":"21","author":"Li","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.it.2026.07.007_bb2120","first-page":"30","article-title":"A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative","volume":"7","author":"Sheikhpour","year":"2018","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"10.1016\/j.it.2026.07.007_bb2125","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.it.2026.07.007_bb2130","doi-asserted-by":"crossref","first-page":"32722","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.it.2026.07.007_bb2135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/jcm8060842","article-title":"Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways","volume":"8","author":"Park","year":"2019","journal-title":"JCM"},{"key":"10.1016\/j.it.2026.07.007_bb2140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","article-title":"Metabolic reprogramming of natural killer cells in obesity limits antitumor responses","volume":"19","author":"Michelet","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2145","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","article-title":"Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer","volume":"15","author":"Croizer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.07.007_bb2150","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-\u03b21","volume":"182","author":"Li","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2155","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41591-025-03981-4","article-title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","volume":"31","author":"Modi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2165","article-title":"Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30","volume":"33","author":"Fournier","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.it.2026.07.007_bb2170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2175","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fimmu.2018.00814","article-title":"Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing \u03b3\u03b4 T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells","volume":"9","author":"Oberg","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.07.007_bb2180","first-page":"13","article-title":"The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity","volume":"9","author":"Wang","year":"2026","journal-title":"Antib. Ther."},{"key":"10.1016\/j.it.2026.07.007_bb2185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41523-024-00618-6","article-title":"High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer","volume":"10","author":"Mei","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb2190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-024-02075-y","article-title":"Novel humanized monoclonal antibodies against ROR1 for cancer therapy","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb2195","article-title":"Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis","volume":"13","author":"Wang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.07.007_bb2200","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1016\/j.ymthe.2025.04.033","article-title":"ErbB2\/HER2-targeted CAR-NK cells eliminate breast cancer cells in an organoid model that recapitulates tumor progression","volume":"33","author":"R\u00f6der","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2026.07.007_bb2205","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2\/HER2-Specific Chimeric Antigen Receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2026.07.007_bb2210","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.it.2026.07.007_bb2215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.it.2026.07.007_bb2220","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.3390\/ijms24109038","article-title":"Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.it.2026.07.007_bb2225","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2230","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2023.41.16_suppl.2508","article-title":"Phase 1\/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results","volume":"41","author":"Safran","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.it.2026.07.007_bb2235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.07.007_bb2240","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy\u2013safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.it.2026.07.007_bb2245","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","article-title":"Cord blood natural killer cells expressing a dominant negative TGF-\u03b2 receptor: Implications for adoptive immunotherapy for glioblastoma","volume":"19","author":"Yvon","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.it.2026.07.007_bb2250","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin A suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat. Immunol."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:05:35Z","timestamp":1786737935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490626001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"alternative-id":["S1471490626001869"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2026.07.007","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NK cells in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}